DrugPatentWatch Database Preview
Email this page to a colleagueSee Plans and Pricing
« Back to Dashboard
INCB039110 is an investigational drug.
There have been 34 clinical trials for INCB039110. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2017.
The most common disease conditions in clinical trials are Graft vs Host Disease, Carcinoma, Non-Small-Cell Lung, and Lung Neoplasms. The leading clinical trial sponsors are Incyte Corporation, National Cancer Institute (NCI), and M.D. Anderson Cancer Center.
There are twenty US patents protecting this investigational drug and two hundred and seventeen international patents.
Recent Clinical Trials for INCB039110
|Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant||National Cancer Institute (NCI)||Phase 1|
|Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant||M.D. Anderson Cancer Center||Phase 1|
|Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation||National Cancer Institute (NCI)||Phase 2|
Top disease conditions for INCB039110
Top clinical trial sponsors for INCB039110
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|INCB039110||Start Trial||Bicyclic fused pyrimidine compounds as TAM inhibitors||Incyte Corporation (Wilmington, DE)||Start Trial|
|INCB039110||Start Trial||Pyrrolopyrimidine derivatives as TAM inhibitors||Incyte Corporation (Wilmington, DE)||Start Trial|
|INCB039110||Start Trial||Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors||Incyte Corporation (Wilmington, DE)||Start Trial|
|INCB039110||Start Trial||Heterocyclic compounds as PI3K-.gamma. inhibitors||Incyte Corporation (Wilmington, DE)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|INCB039110||World Intellectual Property Organization (WIPO)||2017027717||2035-08-12||Start Trial|
|INCB039110||World Intellectual Property Organization (WIPO)||2017035366||2035-08-26||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|